Mostrar 1 - 20 resultats de 40 per cerca 'Tadeusz Robak', hora de la petició: 0.04sec
Refinar resultats
-
1
APPLICATION OF NEW DRUGS IN CHRONIC LYMPHOCYTIC LEUKEMIA per Tadeusz Robak
Publicat 2010-05-01
Article -
2
APPLICATION OF NEW DRUGS IN CHRONIC LYMPHOCYTIC LEUKEMIA per Tadeusz Robak
Publicat 2010-05-01
Article -
3
Editorial: Novel targeted drugs for indolent lymphoid malignancies per Tadeusz Robak, Tadeusz Robak, Bartosz Puła, Iwona Hus
Publicat 2023-06-01
Article -
4
-
5
-
6
Chronic lymphocytic leukemia per Tadeusz Robak, (Coordinating Author)
Publicat 2019-06-01
Article -
7
Bortezomib for the Treatment of Hematologic Malignancies: 15 Years Later per Pawel Robak, Tadeusz Robak
Publicat 2019-04-01
Article -
8
-
9
-
10
-
11
-
12
-
13
Circulating Total and Active Metalloproteinase-9 and Tissue Inhibitor of Metalloproteinases-1 in Patients with Systemic Lupus Erythomatosus per Ewa Robak, Agnieszka Wierzbowska, Magdalena Chmiela, Liliana Kulczycka, Anna Sysa-Jedrejowska, Tadeusz Robak
Publicat 2006-01-01
Article -
14
-
15
-
16
-
17
-
18
Lymphocytes Tγδ in clinically normal skin and peripheral blood of patients with systemic lupus erythematosus and their correlation with disease activity per Ewa Robak, Hanna Niewiadomska, Tadeusz Robak, Jacek Bartkowiak, Jerzy Z. Blonski, Anna Wozniacka, Lech Pomorski, Anna Sysa-Jedrzejowska
Publicat 2001-01-01
Article -
19
Safety and efficacy of acalabrutinib plus bendamustine and rituximab in patients with treatment-naive or relapsed / refractory mantle cell lymphoma: phase Ib trial per Tycel Phillips, Michael Wang, Tadeusz Robak, David Gallinson, Don Stevens, Krish Patel, Safaa Ramadan, Chuan-Chuan Wun, Wojciech Jurczak, Stephen D. Smith
Publicat 2024-09-01
Article -
20
P1094: SAFETY AND EFFICACY OF ACALABRUTINIB, BENDAMUSTINE, AND RITUXIMAB IN PATIENTS WITH TREATMENT-NAIVE OR RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA: PHASE IB TRIAL per Tycel Phillips, Michael Wang, Tadeusz Robak, David Gallinson, Don Stevens, Krish Patel, Safaa Ramadan, Chuan-Chaun Wun, Wojciech Jurczak, Stephen D. Smith
Publicat 2023-08-01
Article